Andreu-Vieyra Claudia V, Berenson James R
Oncotherapeutics, West Hollywood, CA, USA.
Institute for Myeloma and Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA 90069, USA.
Ther Adv Hematol. 2014 Dec;5(6):197-210. doi: 10.1177/2040620714552614.
Panobinostat is an investigational and potent histone deacetylase inhibitor (HDACi) that has shown promise as an antimultiple myeloma agent in the preclinical setting. In this review, we discuss the rationale for the use of panobinostat as a combination therapy for multiple myeloma and provide an overview of recent and ongoing clinical trials testing the safety and efficacy of panobinostat for the treatment of the disease.
帕比司他是一种处于研究阶段的强效组蛋白去乙酰化酶抑制剂（HDACi），在临床前研究中已显示出作为抗多发性骨髓瘤药物的潜力。在本综述中，我们讨论了将帕比司他用作多发性骨髓瘤联合治疗药物的理论依据，并概述了近期及正在进行的测试帕比司他治疗该疾病安全性和有效性的临床试验。
